Research Article

The Prognostic Value of Baseline Lymphocyte, Neutrophil, and Monocyte Counts in Locally Advanced Cervical Carcinoma Treated with Radiation

Table 4

Multivariate analysis of potential factors associated with OS and PFS.

Variable Overall survival Progression-free survival
Hazard ratio [95% CI]Hazard ratio [95% CI]

Age (years)1.00 [0.98–1.02]1.00 [0.99–1.02]0.659
Race
 WhiteReferenceReference
 Black1.30 [0.27–6.26]0.7421.26 [0.37–4.29]0.714
 Other1.36 [0.27–6.61]0.7071.19 [0.35–4.07]0.785
BMI (kg/m2)1.00 [0.97–1.02]0.8991.00 [0.98–1.03]0.925
Smoker
 SmokerReferenceReference
 Nonsmoker1.37 [0.79–2.37]0.2671.08 [0.68–1.72]0.737
Histology
 SquamousReferenceReference
 Adenocarcinoma0.06 [0.01–0.64]0.0200.23 [0.03–1.90]0.167
 Adenosquamous0.10 [0.01–1.14]0.0630.44 [0.05–4.07]0.471
Stage
 IB2ReferenceReference
 IIA0.37 [0.12–1.21]0.0990.42 [0.18–1.00]0.050
 IIB0.28 [0.07–1.14]0.0750.33 [0.12–0.85]0.022
 IIIA0.69 [0.25–1.88]0.4630.40 [0.18–0.89]0.025
 IIIB1.61 [0.47–5.55]0.4490.48 [0.14–1.62]0.235
 IVA1.28 [0.52–3.12]0.5900.92 [0.46–1.84]0.822
Treatment
 RT aloneReferenceReference
 CRT1.65 [0.63–4.31]0.3051.64 [0.74–3.60]0.221
Circulating Neutrophil count1.08 [0.99–1.17]0.1021.12 [1.03–1.21]0.006
Circulating Lymphocyte count0.67 [0.47–0.96]0.0270.79 [0.60–1.06]0.113
Circulating Monocyte count1.08 [0.99–1.17]0.2011.07 [0.49–2.35]0.858